MediciNova (MNOV)

• Market cap: $66.4M
• 1 day: -4.93%
• 5 days: -2.88%
• 1 month: 0.75%
• 3 months: -7.53%
• 6 months: -19.64%
• Year to date: 1.5%
• 1 year: 9.76%
• 5 years: -64.38%
• 10 years: -80.35%
• Sector: Healthcare
• Industry: Biotechnology

About: MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Employees: 6